Free Trial

Suraj Kalia Analyst Performance

Analyst at Oppenheimer

Suraj Kalia is a stock analyst at Oppenheimer focused in the medical sector, covering 30 publicly traded companies. Over the past year, Suraj Kalia has issued 7 stock ratings, including buy and hold recommendations. While full access to Suraj Kalia's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Suraj Kalia's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
96 Last 11 Years
Buy Recommendations
61.70% 58 Buy Ratings
Companies Covered
30 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy61.7%58 ratings
Hold26.6%25 ratings
Sell11.7%11 ratings

Out of 94 total stock ratings issued by Suraj Kalia at Oppenheimer, the majority (61.7%) have been Buy recommendations, followed by 26.6% Hold and 11.7% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
80.0% of companies on NASDAQ
24 companies
NYSE
20.0% of companies on NYSE
6 companies

Suraj Kalia, an analyst at Oppenheimer, currently covers 30 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
26 companies
86.7%
Miscellaneous
4 companies
13.3%

Suraj Kalia of Oppenheimer specializes in stock coverage within the Medical sector, with additional focus on companies.

Coverage Industries

IndustryPercentage
SURGICAL & MEDICAL INSTRUMENTS
8 companies
26.7%
MED INSTRUMENTS
6 companies
20.0%
MED PRODUCTS
5 companies
16.7%
Miscellaneous
4 companies
13.3%
MED - BIOMED/GENE
3 companies
10.0%
ELECTROMEDICAL EQUIPMENT
2 companies
6.7%
MEDICAL INFO SYS
1 company
3.3%
PHARMACEUTICAL PREPARATIONS
1 company
3.3%

Suraj Kalia's Ratings History at Oppenheimer

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
9/2/2025Upgrade$40.17$60.00Outperform
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
7/7/2025Initiated Coverage$59.00Market Perform
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
7/7/2025Initiated Coverage$14.80$22.00Outperform
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
6/17/2025Boost Price Target$141.06$150.00Outperform
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
5/9/2025Boost Price Target$114.47$130.00Outperform
AtriCure, Inc. stock logo
ATRC
AtriCure
2/13/2025Boost Price Target$38.82$45.00Outperform
VAREX IMAGING stock logo
VREX
VAREX IMAGING
2/7/2025Lower Price Target$12.12$23.00Outperform